CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial.

Willenbrock F., Cox C., Wilhelm-Benartzic C., Owens R., Sabbagh A., Abraham A., Maughan T., Hurt C., O'Neill E., Mukherjee S.

DOI

10.1093/annonc/mdz156.001

Type

Conference paper

Publication Date

07/2019

Volume

30 Suppl 4

Permalink Original publication